Chronic myelogenous leukemia: Monitoring response to therapy

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 75-81

  Branford, Susan ^a   Prime, Jodi ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SA Pathology ^*  (Australia)

Author keywords

BCR ABL quantitative PCR; Ceasing therapy; Chronic myeloid leukemia; Kinase inhibitors; Major molecular response; Molecular monitoring; Standardization

Indexed keywords

BCR ABL PROTEIN; DASATINIB; MESSENGER RNA; NILOTINIB;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; CYTOGENETICS; GENOMICS; HUMAN; LIMIT OF DETECTION; MICROARRAY ANALYSIS; MONITORING; PATIENT CARE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RNA DEGRADATION; RNA EXTRACTION; RNA TRANSCRIPTION; ROOM TEMPERATURE; STANDARDIZATION; TREATMENT RESPONSE;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES;

EID: 79957472531     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0082-1     Document Type: Article

References (43)

1. BJ Druker F Guilhot SG O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 17151364 10.1056/NEJMoa062867 1:CAS:528:DC%2BD28Xht12ntrzM (Pubitemid 44903745)
2. • Saglio G, Kim DW, Issaragrisil S, et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-2259. The use of nilotinib as first-line therapy resulted in higher rates of MMR and improved PFS compared with imatinib.
3. • Kantarjian H, Shah NP, Hochhaus A, et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270. Dasatinib as first-line therapy proved superior to imatinib for both molecular and cytogenetic response.
4. A Hochhaus SG O'Brien F Guilhot, et al. 2009 Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 1054 1061 19282833 10.1038/leu.2009.38 1:CAS:528: DC%2BD1MXntFygt7w%3D
5. S Branford JF Seymour A Grigg, et al. 2007 BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria Clin Cancer Res 13 7080 7085 18056186 10.1158/1078-0432. CCR-07-0844 1:CAS:528:DC%2BD2sXhtlyitL%2FL (Pubitemid 350276891)
6. • Baccarani M, Cortes J, Pane F, et al.: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-6051. This paper provides recommendations for therapeutic intervention according to the achievement of kinase inhibitor milestone responses or loss of response.
7. • Mahon FX, Rea D, Guilhot J, et al.: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035. This article demonstrates that discontinuation of imatinib can be followed by stable remission in a substantial proportion of patients who have a stable CMR for at least 2 years before imatinib cessation.
8. DM Ross S Branford JF Seymour, et al. 2010 Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR Leukemia 24 1719 1724 20811403 10.1038/leu.2010.185 1:CAS:528:DC%2BC3cXht1OmtbjN
9. DM Ross S Branford S Moore TP Hughes 2006 Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL Leukemia 20 664 670 16482210 10.1038/sj.leu.2404139 1:CAS:528:DC%2BD28XivVyrsbY%3D
10. • Hughes TP, Hochhaus A, Branford S, et al.: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood. 2010;116:3758-3765. This study is the longest molecular follow-up in patients treated with first-line imatinib. It demonstrated that BCR-ABL1 values measured early in therapy provide prognostic insight and can be used as a surrogate to assess the cytogenetic response.
11. S Branford L Fletcher NCP Cross, et al. 2008 Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 3330 3338 18684859 10.1182/blood-2008-04-150680 1:CAS:528:DC%2BD1cXht1Omur3M
12. MC Muller NCP Cross P Erben, et al. 2009 Harmonization of molecular monitoring of CML therapy in Europe Leukemia 23 1957 1963 19710700 10.1038/leu.2009.168 1:STN:280:DC%2BD1MjltFekuw%3D%3D
13. MJ Mauro BJ Druker RT Maziarz 2004 Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission Leuk Res 28 Suppl 1 S71 S73 15036945 10.1016/j.leukres.2003.10.017 1:CAS:528:DC%2BD2cXhsVOgurc%3D (Pubitemid 38251502)
14. J Cortes S O'Brien H Kantarjian 2004 Discontinuation of imatinib therapy after achieving a molecular response Blood 104 2204 2205 15377577 10.1182/blood-2004-04-1335 1:CAS:528:DC%2BD2cXotVyjsrs%3D (Pubitemid 39297882)
15. F Michor TP Hughes Y Iwasa, et al. 2005 Dynamics of chronic myeloid leukaemia Nature 435 1267 1270 15988530 10.1038/nature03669 1:CAS:528: DC%2BD2MXls1Ontbo%3D (Pubitemid 40943094)
16. A Burchert MC Muller P Kostrewa, et al. 2010 Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia J Clin Oncol 28 1429 1435 20142590 10.1200/JCO.2009.25.5075 1:CAS:528:DC%2BC3cXksFSqurk%3D
17. FJ Giles M O'Dwyer R Swords 2009 Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Leukemia 23 1698 1707 19474800 10.1038/leu.2009.111 1:CAS:528:DC%2BD1MXht1GgtLjK
18. RD Press C Galderisi R Yang, et al. 2007 A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 6136 6143 17947479 10.1158/1078-0432.CCR-07-1112 1:CAS:528:DC%2BD2sXhtFygsL7N (Pubitemid 350075073)
19. S Branford R Lawrence A Grigg, et al. 2008 Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response ASH Annual Meeting Abstracts 112 2113
20. M Colombat MP Fort C Chollet, et al. 2006 Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment Haematologica 91 162 168 16461299 1:CAS:528:DC%2BD28XisFWrs7k%3D
21. H Kantarjian S O'Brien J Shan, et al. 2008 Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112 837 845 18085610 10.1002/cncr.23238 (Pubitemid 351240578)
22. T Hughes M Deininger A Hochhaus, et al. 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37 16522812 10.1182/blood-2006-01-0092 1:CAS:528:DC%2BD28XmsVOmt7Y%3D (Pubitemid 43990609)
23. I Thorn U Olsson-Stromberg C Ohlsen, et al. 2005 Impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia Haematologica 90 1350 1355
24. B Kagedal M Lindqvist M Farneback, et al. 2005 Failure of the PAXgene Blood RNA System to maintain mRNA stability in whole blood Clin Chem Lab Med 43 1190 1192 16232084 10.1515/CCLM.2005.206 (Pubitemid 41600669)
25. A Hochhaus MC Muller J Radich, et al. 2009 Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value Leukemia 23 1628 1633 19641527 10.1038/leu.2009.156 1:CAS:528:DC%2BD1MXhtV2rtrjF
26. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In: Illand H, Hertzgerg M, Marlton P, editors. Myeloid leukemia: methods and protocols, methods in molecular medicine. Totowa: Humana; 2006. p. 69-92.
27. TP Hughes J Kaeda S Branford, et al. 2003 Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 1432 14534335 10.1056/NEJMoa030513 1:CAS:528:DC%2BD3sXotVGgs7s%3D (Pubitemid 37211057)
28. N Raghavachari X Xu PJ Munson MT Gladwin 2009 Characterization of whole blood gene expression profiles as a sequel to globin mRNA reduction in patients with sickle cell disease PLoS ONE 4 e6484 19649296 10.1371/journal.pone.0006484
29. C Wright D Bergstrom H Dai, et al. 2008 Characterization of globin RNA interference in gene expression profiling of whole-blood samples Clin Chem 54 396 405 18089658 10.1373/clinchem.2007.093419 1:CAS:528:DC%2BD1cXhs1Clsr8%3D (Pubitemid 351302623)
30. LA Field RM Jordan JA Hadix, et al. 2007 Functional identity of genes detectable in expression profiling assays following globin mRNA reduction of peripheral blood samples Clin Biochem 40 499 502 17303101 10.1016/j.clinbiochem. 2007.01.004 1:CAS:528:DC%2BD2sXjslSksLg%3D (Pubitemid 46483331)
31. D Ross PA Bartley AA Morley, et al. 2007 Detection of patient-specific BCR-ABL genomic DNA in CML patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR Haematologica 92 s1 212
32. F-X Mahon S Dulucq F Guilhot, et al. 2010 A more sensitive RQ-PCR to assess complete molecular remission does not allow the prediction of relapse after discontinuation of imatinib in chronic myeloid leukemia ASH Annual Meeting Abstracts 116 2298
33. M Sobrinho-Simoes V Wilczek J Score, et al. 2010 In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib Blood 116 1329 1335 20462961 10.1182/blood-2009-11-255109 1:CAS:528:DC%2BC3cXhtFersbbE
34. PA Bartley MH Martin-Harris BJ Budgen, et al. 2010 Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia Br J Haematol 149 231 236 20067557 10.1111/j.1365-2141.2009.08071.x 1:CAS:528:DC%2BC3cXmtFCku7w%3D
35. PA Bartley DM Ross S Latham, et al. 2010 Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA Int J Lab Hematol 32 e222 e228 20491997 10.1111/j.1751-553X.2010.01236.x 1:STN:280:DC%2BC3cbit1yksw%3D%3D
36. S Branford Z Rudzki I Parkinson, et al. 2004 Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2926 2932 15256429 10.1182/blood-2004-03-1134 1:CAS:528:DC%2BD2cXpslKjurc%3D (Pubitemid 39434981)
37. L Wang K Knight C Lucas RE Clark 2006 The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia Haematologica 91 235 239 16461309 1:CAS:528:DC%2BD28XisFWrsLs%3D
38. RD Press SG Willis J Laudadio, et al. 2009 Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood 114 2598 2605 19625707 1:CAS:528:DC%2BD1MXht1eit7rE
39. D Marin JS Khorashad L Foroni, et al. 2009 Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 145 373 375 19344397 10.1111/j.1365-2141.2009.07646.x 1:CAS:528:DC%2BD1MXlslOhs7w%3D
40. DW Sherbenou MJ Wong A Humayun, et al. 2007 Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib Leukemia 21 489 493 17252009 10.1038/sj.leu.2404554 1:CAS:528:DC%2BD2sXhvFWktrY%3D
41. S Branford NCP Cross A Hochhaus, et al. 2006 Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Leukemia 20 1925 1930 16990771 10.1038/sj.leu.2404388 1:CAS:528:DC%2BD28XhtFWnsL3O (Pubitemid 44614879)
42. HM Kantarjian J Shan D Jones, et al. 2009 Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response J Clin Oncol 27 3659 3663 19487383 10.1200/JCO.2008.18.6999
43. • White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:e111-117. This paper outlined the development of the first certified material for the standardization of RQ-PCR methods.